Analytical methods for brain targeted delivery system in vivo: Perspectives on imaging modalities and microdialysis

Journal of Pharmaceutical and Biomedical Analysis

Volumn 59, Issue 1, 2012, Pages 1-12

  Zhang, Xingguo ^a,b   Liu, Lin ^b   Zhang, XiangYi ^b   Ma, Kuifen ^b   Rao, Yuefeng ^b   Zhao, Qingwei ^b   Li, Fanzhu ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Brain targeting; Drug delivery; Imaging modalities; Mircodialysis; Neurotransmitter

Indexed keywords

ANALYTIC METHOD; BLOOD BRAIN BARRIER; BRAIN; BRAIN DISEASE; CEREBROSPINAL FLUID; DRUG DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; MICRODIALYSIS; PHARMACEUTICAL PREPARATIONS;

EID: 82255192066     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.08.042     Document Type: Review

References (173)

1. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug nanoparticles?. Drug Discov. Today 2008, 13:1099-1106.
2. Schultz K.N., Kennedy R.T. Time-resolved microdialysis for in vivo neurochemical measurements and other applications. Annu. Rev. Anal. Chem. 2008, 1:627-661.
3. Taggart D.P., Choudhary B., Anastasiadis K., et al. Preliminary experience with a novel intraoperative fluorescence imaging technique to evaluate the patency of bypass grafts in total arterial revascularization. Ann. Thorac. Surg. 2003, 75:870-873.
4. Chen J., Tung C.H., Allport J.R., et al. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005, 111:1800-1805.
5. Sosnovik D.E., Schellenberger E.A., Nahrendorf M., et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magnetooptical nanoparticle. Magn. Reson. Med. 2005, 54:718-724.
6. Ntziachristos V., Tung C.H., Bremer C., et al. Fluorescence molecular tomography resolves protease activity in vivo. Nat. Med. 2002, 8:757-761.
7. Razansky D., Distel M., Vinegoni C., et al. Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nat. Photonics 2009, 3:412-417.
8. Pan Y.F., Feng J., Cheng Q.Y., Li F.Z. Intracerebral microdialysis technique and its application on brain pharmacokinetic-pharmacodynamic study. Arch. Pharm. Res. 2007, 30:1635-1645.
9. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104:29-45.
10. Persidsky Y., Ramirez S., Haorah J., Kanmogne G. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 2006, 1:223-236.
11. Chen Y., Dalwadi G., Benson H. Drug delivery across the blood-brain barrier. Curr. Drug Deliv. 2004, 1:361-376.
12. Olivier J.C. Drug transport to brain with targeted nanoparticles. NeuroRx 2005, 2:108-119.
13. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 2002, 70:1781-1792.
14. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
15. Brightman M.W., Reese T.S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 1969, 40:648-677.
16. Saunders N.R., Ek C.J., Habgood M.D., et al. Barriers in the brain: a renaissance?. Trends Neurosci. 2008, 31:279-286.
17. Saunders N., Habgood M.D., Dziegielewska K. Barrier mechanisms in the brain, II. Immature brain. Clin. Exp. Pharmacol. Physiol. 1999, 26:85-91.
18. Saunders N., Habgood M.D., Dziegielewska K. Barrier mechanisms in the brain, I. Adult brain. Clin. Exp. Pharmacol. Physiol. 1999, 26:11-19.
19. Giovagnoli S., Blasi P., Schoubben A., et al. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int. J. Pharm. 2007, 333:103-111.
20. Jovanovic I., Jordovic B., Petkovic M., et al. Preparation of smallest microparticles of poly-d,l-lactide by modified precipitation method: influence of the process parameters. Microsc. Res. Tech. 2008, 71:86-92.
21. Noda A., Takamatsu H., Murakami Y., et al. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. J. Nucl. Med. 2003, 44:105-108.
22. Tan Y., Jiang H. DOT guided fluorescence molecular tomography of arbitrarily shaped objects. Med. Phys. 2008, 35:5703-5707.
23. Ntziachristos V., Bremer C., Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 2003, 13:195-208.
24. Freed A.L., Cooper J.D., Davies M.I., et al. Investigation of the metabolism of substance P in rat striatum by microdialysis sampling and capillary electrophoresis with laser-induced fluorescence detection. J. Neurosci. Methods 2001, 109:23-29.
25. Kostel K.L., Lunte S.M. Evaluation of capillary electrophoresis with postcolumn derivatization and laser-induced fluorescence detection for the determination of substance P and its metabolites. J. Chromatogr. B: Biomed. Sci. Appl. 1997, 695:27-38.
26. McLaughlin K.J., Faibushevich A.A., Lunte C.E. Microdialysis sampling with online microbore HPLC for the determination of tirapazamine and its reduced metabolites in rats. Analyst 2000, 125:105-110.
27. Benveniste H., Huttemeier P.C. Microdialysis - theory and application. Prog. Neurobiol. 1990, 35:195-215.
28. Groth L., García Ortiz P., Benfeldt E. Microdialysis methodology for sampling in the skin. Handbook of Non-Invasive Methods and the Skin 2006, 443-454. Taylor & Francis, Boca Raton. J. Serup, G.B.E. Jemec, G.L. Grove (Eds.).
29. Borjigin J., Liu T. Application of long-term microdialysis in circadian rhythm research. Pharmacol. Biochem. Behav. 2008, 90:148-155.
30. Benveniste H., Drejer J., Schousboe A., et al. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 1984, 43:1369-1374.
31. de Lange E.C., Danhof M., de Boer A.G., Breimer D.D. Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res. 1994, 666:1-8.
32. Major O., Shdanova T., Duffek L., Nagy Z. Continuous monitoring of blood-brain barrier opening to Cr51-EDTA by microdialysis following probe injury. Acta Neurochir. Suppl. (Wien.) 1990, 51:46-48.
33. Nandi P., Lunte S.M. Recent trends in microdialysis sampling integrated with conventional and microanalytical systems for monitoring biological events: a review. Anal. Chim. Acta 2009, 651:1-14.
34. Westerink B.H., Cremers T.I. Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat. Synapse 2002, 43:238-243.
35. Yang C.S., Tsai P.J. On-line, continuous and automatic monitoring of extracellular malondialdehyde concentration in anesthetized rat brain cortex. J. Chromatogr B: Biomed. Sci. Appl. 2001, 752:33-38.
36. Orlowska-Majdak M., Traczyk W.Z., Szymanski D. Hippocampal vasopressin release evoked by N-methyl d-aspartate (NMDA) microdialysis. Physiol. Res. 2003, 52:373-382.
37. Delgado J.M.R., Lerma J., Martin del Rio R., Solis J.M. Dialytrode technology and local profiles of amino acids in the awake cat brain. J. Neurochem. 1984, 42:1218-1228.
38. Brunner M., Derendorf H. Clinical microdialysis: current applications and potential use in drug development, TrAC. Trends Anal. Chem. 2006, 25:674-680.
39. Chen Q., Gong T., Liu J., et al. Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J. Drug Target 2009, 17:318-328.
40. Doijad R.C., Manvi F.V., Godhwani D.M., et al. Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Ind. J. Pharm. Sci. 2008, 70:203-207.
41. Wilson B., Samanta M., Santhi K., et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 2008, 70:75-84.
42. Huang G., Zhang N., Bi X.L., et al. Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int. J. Pharm. 2008, 355:314-320.
43. Parikh T., Bommana M., Squillante E., et al. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur. J. Pharm. Biopharm. 2010, 74:442-450.
44. Sigler A., Goroshkov A., Murphy T.H. Hardware and methodology for targeting single brain arterioles for photothrombotic stroke on an upright microscope. J. Neurosci. Methods 2008, 170:35-44.
45. Riviere C., Martina M., Tomita Y., et al. Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. Radiology 2007, 244:439-448.
46. Tang S.N., Liu Z.H., Zhao L.X., et al. Transfection of pEGFP-C2 in brain mediated by targeting liposome P-MMA-DOSPER. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2008, 25:1170-1174.
47. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
48. Ntziachristos V., Yodh A.G., Schnall M.D., Chance B. MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. Neoplasia 2002, 4:347-354.
49. Grimm J., Kirsch D.G., Windsor S.D., et al. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14404-14409.
50. Ntziachristos V., Tung C.H., Bremer C., Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat. Med. 2002, 8:757-760.
51. Sosnovik D.E., Nahrendorf M., Deliolanis N., et al. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 2007, 115:1384-1391.
52. Corlu A., Choe R., Durduran T., et al. Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt. Express 2007, 15:6696-6716.
53. Graves E., Ripoll J., Weissleder R., Ntziachristos V. A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med. Phys. 2003, 30:901-911.
54. Andreas L., Albrecht F., Kiderlen B., et al. Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas. Nanomedicine 2010, 6:597-603.
55. Leupold E., Nikolenko H., Beyermann M., et al. Insight into the role of HSPG in the cellular uptake of apolipoprotein E-derived peptide micelles and liposomes. Biochim. Biophys. Acta. 2008, 1778:2781-2789.
56. Kwon E.J., Lasiene J., Jacobson B.E., et al. Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone. Biomaterials 2010, 31:2417-2424.
57. Adam J.F., Biston M.C., Rousseau J., et al. Heavy element enhanced synchrotron stereotactic radiotherapy as a promising brain tumour treatment. Phys. Med. 2008, 24:92-97.
58. Meng Q.G., Yu M., Gu B., et al. Myristic acid-conjugated polyethylenimine for brain-targeting delivery: in vivo and ex vivo imaging evaluation. J. Drug Target. 2010, 18:438-446.
59. Schambach S.J., Bag S., Groden C., et al. Vascular imaging in small rodents using micro-CT. Methods 2010, 50:26-35.
60. Mulik R.S., Monkkonen J., Juvonen R.O., et al. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol. Pharm. 2010, 7:815-825.
61. Edouard M., Broggio D., Prezado Y., et al. Treatment plans optimization for contrast-enhanced synchrotron stereotactic radiotherapy. Med. Phys. 2010, 37:2445-2456.
62. Craparo E.F., Ognibene M.C., Casaletto M.P. Biocompatible polymeric micelles with polysorbate 80 for use in brain targeting. Nanotechnology 2008, 19:1-12.
63. Pan J., Feng S.S. Targeted delivery of paclitaxel using folate-decorated poly(lactide) - vitamin E TPGS nanoparticles. Biomaterials 2008, 29:2663-2672.
64. Caire F., Gantois C., Torny F. Intraoperative use of the Medtronic O-arm for deep brain stimulation procedures. Stereotact. Funct. Neurosurg. 2010, 88:109-114.
65. Armour M., Ford E., Iordachita I. CT guidance is needed to achieve reproducible positioning of the mouse head for repeat precision cranial irradiation. Radiat. Res. 2010, 173:119-123.
66. Chan F., Meng, Kassim I., et al. Image-guided robotic neurosurgery-an in vitro and in vivo point accuracy evaluation experimental study. Surg. Neurol. 2009, 71:640-648.
67. Hirano L.A., Bogardus S.T., Saluja S., et al. Clinical yield of computed tomography brain scans in older general medical patients. J. Am. Geriatr. Soc. 2006, 54:587-592.
68. Fowler J.S., Volkow N.D., Wang G.J., et al. PET and drug research and development. J. Nucl. Med. 1999, 40:1154-1163.
69. Gatley S.J., Volkow N.D., Wang G.J., et al. PET imaging in clinical drug abuse research. Curr. Pharm. Des. 2005, 11:3203-3219.
70. Volkow N.D., Wang G.J., Fowler J.S., et al. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1410-1415.
71. Langen K.J., Hamacher K., Weckesser M., et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl. Med. Biol. 2006, 33:287-294.
72. Price P. The role of PET scanning in determining pharmacoselective doses in oncology drug development. Ernst. Schering Res. Found Workshop 2007, 185-193.
73. Oku N., Yamashita M., Katayama Y., et al. PET imaging of brain cancer with positron emitter-labeled liposomes. Pharm. Nanotechnol. 2011, 403:170-177.
74. Benveniste H., Fowler J.S., Rooney W., et al. Maternal and fetal 11C-cocaine uptake and kinetics measured in vivo by combined PET and MRI in pregnant nonhuman primates. J. Nucl. Med. 2005, 46:312-320.
75. Alonzi R., Hoskin P. Functional imaging in clinical oncology: magnetic resonance imaging- and computerised tomography-based techniques. Clin. Oncol. 2006, 18:555-570.
76. Li J.Y., Boado R.J., Pardridge W.M. Blood-brain barrier genomics. J. Cereb. Blood Flow Metab. 2001, 21:61-68.
77. Chopp M., Zhang Z.G., Jiang Q. Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke 2007, 38:827-831.
78. Nelson S.J., Cha S. Imaging glioblastoma multiforme. Cancer J. 2003, 9:134-145.
79. Young R.J., Knopp E.A. Brain MRI: tumor evaluation. J. Magn. Reson Imaging 2006, 24:709-724.
80. Li D.K., Li M.J., Traboulsee A., et al. The use of MRI as an outcome measure in clinical trials. Adv. Neurol. 2006, 98:203-226.
81. William T.C., Christoforidis G.A., Koch R.M., et al. Clinical magnetic resonance imaging of brain tumors at ultrahigh field: a state-of-the-art review. Top. Magn. Reson. Imaging 2006, 17:53-61.
82. Sun C., Lee J., Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1252-1265.
83. Liu H.L., Hua M.Y., Yang H.W., et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15205-15210.
84. Veiseh O., Kievit F.M., Fang C., et al. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 2010, 31:8032-8042.
85. Liu W., Frank J.A. Detection and quantification of magnetically labeled cells by cellular MRI. Eur. J. Radiol. 2009, 70:258-264.
86. Chertok B., Moffat B.A., David A.E., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
87. Hsu S.H., Wen C.J., AI-Suwayeh S.A., et al. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology 2010, 40:405101.
88. Xu R.X., Povoski S.P. Diffuse optical imaging and spectroscopy for cancer. Expert Rev. Med. Devices 2007, 4:83-95.
89. Wang Q., Liu Z., Jiang H.B. Optimization and evaluation of a three-dimensional diffuse optical tomography system for brain imaging. J. X-ray Sci. Technol. 2007, 15:223-234.
90. Mahmood U., Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2003, 2:489-496.
91. V. Ntziachristos, R. Weissleder, Fluorescence-mediated molecular tomography, United States Patent US 6615063B1, 2008.
92. Pham W., Zhao B.Q., Lo E.H., et al. Crossing the blood-brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging. Neuroimage 2005, 28:287-292.
93. Graves E.E., Ripoll J.J., Weissleder R., et al. A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med. Phys. 2003, 30:901-911.
94. Razansky D., Baeten J., Ntziachristos V. Sensitivity of molecular target detection by multispectral optoacoustic tomography (MSOT). Med. Phys. 2009, 36:939-945.
95. Kumar M., Misra A., Babbar A.K., et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008, 358:285-291.
96. Chaurasia C.S., Muller M., Bashaw E.D., et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm. Res. 2007, 24:1014-1025.
97. de Lange E.C., Ravenstijn P.G., Groenendaal D., van Steeg T.J. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J. 2005, 7:E532-E543.
98. Masana M., Bortolozzi A., Artigas F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14:53-68.
99. Herrera-Marschitz M., Arbuthnott G., Ungerstedt U. The rotational model and microdialysis: significance for dopamine signalling, clinical studies, and beyond. Prog. Neurobiol. 2010, 90:176-189.
100. de Souza Silva M.A., Mattern C., Topic B., et al. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. Eur. Neuropsychopharmacol. 2009, 19:53-63.
101. de Souza Silva M.A., Topic B., Huston J.P., Mattern C. Intranasal administration of progesterone increases dopaminergic activity in amygdala and neostriatum of male rats. Neuroscience 2008, 157:196-203.
102. Plock N., Kloft C. Microdialysis-theoretical background and recent implementation in applied life-sciences. Eur. J. Pharm. Sci. 2005, 25:1-24.
103. Di Chiara G., Tanda G., Carboni E. Estimation of in-vivo neurotransmitter release by brain microdialysis: the issue of validity. Behav. Pharmacol. 1996, 7:640-657.
104. Sauvinet V., Parrot S., Benturquia N., et al. In vivo simultaneous monitoring of gamma-aminobutyric acid, glutamate, and l-aspartate using brain microdialysis and capillary electrophoresis with laser-induced fluorescence detection: analytical developments and in vitro/in vivo validations. Electrophoresis 2003, 24:3187-3196.
105. Benturquia N., Parrot S., Sauvinet V., et al. Simultaneous determination of vigabatrin and amino acid neurotransmitters in brain microdialysates by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 806:237-244.
106. Yu Y., Sun Q., Zhou T., et al. On-line microdialysis system with poly(amidoamine)-encapsulated Pt nanoparticles biosensor for glutamate sensing in vivo. Bioelectrochemistry 2011, 81:53-57.
107. Klinker C.C., Bowser M.T. 4-Fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorogenic labeling reagent for the in vivo analysis of amino acid neurotransmitters using online microdialysis-capillary electrophoresis. Anal. Chem. 2007, 79:8747-8754.
108. Zhu W., Wang D., Zheng J., et al. Effect of (R)-salsolinol and N-methyl-(R)-salsolinol on the balance impairment between dopamine and acetylcholine in rat brain: involvement in pathogenesis of Parkinson disease. Clin. Chem. 2008, 54:705-712.
109. Kako H., Kobayashi Y., Yokogoshi H. Effects of n-hexanal on dopamine release in the striatum of living rats. Eur. J. Pharmacol. 2011, 651:77-82.
110. Kitaichi Y., Inoue T., Nakagawa S., et al. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J. Pharmacol. 2010, 647:90-96.
111. Li Q., Zubieta J.K., Kennedy R.T. Practical aspects of in vivo detection of neuropeptides by microdialysis coupled off-line to capillary LC with multistage MS. Anal. Chem. 2009, 81:2242-2250.
112. Baseski H.M., Watson C.J., Cellar N.A., et al. Capillary liquid chromatography with MS3 for the determination of enkephalins in microdialysis samples from the striatum of anesthetized and freely-moving rats. J. Mass Spectrom. 2005, 40:146-153.
113. Merali Z., Hayley S., Kent P., et al. Impact of repeated stressor exposure on the release of corticotropin-releasing hormone, arginine-vasopressin and bombesin-like peptides at the anterior pituitary. Behav. Brain Res. 2009, 198:105-112.
114. Hashizume T., Kasuya E. Methodology for the study of the hypothalamic-pituitary hormone secretion in cattle. Anim. Sci. J. 2009, 80:1-11.
115. Marazioti A., Pitychoutis P.M., Papadopoulou-Daifoti Z., et al. Activation of somatostatin receptors in the globus pallidus increases rat locomotor activity and dopamine release in the striatum. Psychopharmacology (Berl.) 2008, 201:413-422.
116. Liu Z., Welin M., Bragee B., et al. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 2000, 21:853-860.
117. Mathe A.A., Rudorfer M.V., Stenfors C., et al. Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin, and neurokinin a concentrations in cerebrospinal fluid of depressed patients: a pilot study. Depression 2008, 3:250-256.
118. Gruber S.H., Nomikos G.G., Mathé A.A. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs. Eur. Neuropsychopharmacol. 2006, 16:592-600.
119. Soucheleau J., Denoroy L. Determination of vasoactive intestinal peptide in rat brain by high-performance capillary electrophoresis. J. Chromatogr. 1992, 608:181-188.
120. Aparicio L.C., Candeletti S., Binaschi A., et al. Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. J. Neurochem. 2004, 91:30-37.
121. España R.A., Melchior J.R., Roberts D.C., et al. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology (Berl.) 2011, 214:415-426.
122. Kiyashchenko L.I., Mileykovskiy B.Y., Maidment N., et al. Release of hypocretin (orexin) during waking and sleep states. J. Neurosci. 2002, 22:5282-5286.
123. Lanckmans K., Sarre S., Smolders I., et al. Use of a structural analogue versus a stable isotope labeled internal standard for the quantification of angiotensin IV in rat brain dialysates using nano-liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:1187-1195.
124. Ihalainen J., Sarajärvi T., Kemppainen S., et al. A novel delayed non-match to sample object recognition task that allows simultaneous in vivo microdialysis. J. Neurosci. Methods 2010, 189:210-215.
125. Takase K., Kimura F., Yagami T., et al. Sex-specific 24-h acetylcholine release profile in the medial prefrontal cortex: simultaneous measurement of spontaneous locomotor activity in behaving rats. Neuroscience 2009, 159:7-15.
126. Hammarlund-Udenaes M. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?. Basic Clin. Pharmacol. Toxicol. 2010, 106:215-220.
127. Clinckers R., Smolders I., Vermoesen K., et al. Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations. Expert Opin. Drug Metab. Toxicol. 2009, 5:1267-1277.
128. Hammarlund-Udenaes M., Friden M., Syvanen S., Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 2008, 25:1737-1750.
129. Kalvass J.C., Maurer T.S., Pollack G.M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab. Dispos. 2007, 35:660-666.
130. Watson J., Wright S., Lucas A., et al. Receptor occupancy and brain free fraction. Drug Metab. Dispos. 2009, 37:753-760.
131. Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv. Drug Deliv. Rev. 2000, 45:283-294.
132. Hammarlund-Udenaes M., Paalzow L.K., de Lange E.C. Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 1997, 14:128-134.
133. Friden M., Ducrozet F., Middleton B., et al. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab. Dispos. 2009, 37:1226-1233.
134. Friden M., Gupta A., Antonsson M., et al. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab. Dispos. 2007, 35:1711-1719.
135. Kalvass J.C., Maurer T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 2002, 23:327-338.
136. Ikeda Y., Oda Y., Nakamura T., et al. Pharmacokinetics of lidocaine, bupivacaine, and levobupivacaine in plasma and brain in awake rats. Anesthesiology 2010, 112:1396-1403.
137. Sheu W.H., Chuang H.C., Cheng S.M., et al. Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. J. Pharm. Biomed. Anal. 2011, 54:759-764.
138. Tsai T.H., Chen Y.F. Simultaneous determination of cefazolin in rat blood and brain by microdialysis and microbore liquid chromatography. Biomed. Chromatogr. 2000, 14:274-278.
139. Cheng F.C., Ho Y.F., Hung L.C., et al. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and highperformance liquid chromatography. J. Chromatogr. A 2002, 949:35-42.
140. Tsai T.H. Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a P-glycoprotein modulator. J. Agric. Food Chem. 2002, 50:6669-6674.
141. Tsai T.H., Chen Y.F. Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography. J. Chromatogr. A 2003, 987:277-282.
142. Sadiq M.W., Salehpour M., Forsgard N., et al. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 2011, 39:174-179.
143. Tunblad K., Ederoth P., Gärdenfors A., et al. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol. Scand. 2004, 48:294-301.
144. Ederoth P., Tunblad K., Bouw R., et al. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br. J. Clin. Pharmacol. 2004, 57:427-435.
145. K. Tunblad, Blood-brain barrier transport of drugs across species with the emphasis on health, disease and modelling, Thesis, Uppsala, 2004.
146. de Lange E.C., Marchand S., van den Berg D., et al. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 2000, 12:85-93.
147. Hoistad M., Chen K.C., Nicholson C., et al. Quantitative dual-probe microdialysis: evaluation of [3H]mannitol diffusion in agar and rat striatum. J. Neurochem. 2002, 81:80-93.
148. Marchand S., Chenel M., Lamarche I., et al. Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. J. Pharm. Sci. 2003, 92:2458-2465.
149. Mindermann T., Zimmerli W., Gratzl O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob. Agents Chemother. 1998, 42:2626-2629.
150. Leggas M., Zhuang Y., Welden J., et al. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. J. Pharm. Sci. 2004, 93:2284-2295.
151. Blakeley J., Portnow J. Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin. Drug Metab. Toxicol. 2010, 6:1477-1491.
152. Meyerson B.A., Linderoth B., Karlsson H., et al. Microdialysis in the human brain: extracellular measurements in the thalamus of Parkinsonian patients. Life Sci. 1990, 46:301-308.
153. Ungerstedt U., Rostami E. Microdialysis in neurointensive care. Curr. Pharm. Des. 2004, 10:2145-2152.
154. Charalambides C., Sgouros S., Sakas D. Intracerebral microdialysis in children. Childs Nerv. Syst. 2010, 26:215-220.
155. Alessandri B., Doppenberg E., Bullock R., et al. Glucose and lactate metabolism after severe human head injury: influence of excitatory neurotransmittersand injury type. Acta Neurochir. Suppl. 1999, 75:21-24.
156. Goodman J.C., Valadka A.B., Gopinath S.P., et al. Extracellular lactate and glucose alterations in the brain after head injury measured by microdialysis. Crit. Care Med. 1999, 27:1965-1973.
157. Hillered L., Persson L., Nilsson P., et al. Continuous monitoring of cerebral metabolism in traumatic brain injury: a focus on cerebral microdialysis. Curr. Opin. Crit. Care 2006, 12:112-118.
158. Maurer M.H., Haux D., Sakowitz O.W., et al. Identification of early markers for symptomatic vasospasm in human cerebral microdialysate after subarachnoid hemorrhage: preliminary results of a proteome-wide screening. J. Cereb. Blood Flow Metab. 2007, 27:1675-1683.
159. Skjøth-Rasmussen J., Schulz M., Kristensen S.R., et al. Delayed neurological deficits detected by an ischemic pattern in the extracellular cerebral metabolites in patients with aneurysmal subarachnoid hemorrhage. J. Neurosurg. 2004, 100:8-15.
160. Schlenk F., Graetz D., Nagel A., et al. Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage. Crit. Care 2008, 12:R9.
161. Schneweis S., Grond M., Staub F., et al. Predictive value of neurochemical monitoring in large middle cerebral artery infarction. Stroke 2001, 32:1863-1867.
162. Hlatky R., Valadka A.B., Goodman J.C., et al. Patterns of energy substrates during ischemia measured in the brain by microdialysis. J. Neurotrauma 2004, 21:894-906.
163. Blakeley J.O., Olson J., Grossman S.A., et al. Consortium. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J. Neurooncol. 2009, 91:51-58.
164. Portnow J., Badie B., Chen M., et al. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin. Cancer Res. 2009, 15:7092-7098.
165. Lindberger M., Tomson T., Wallstedt L., et al. Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study. Epilepsia 2001, 42:256-261.
166. Lindberger M., Tomson T., Lars S. Microdialysis sampling of carbamazepine, phenytoin and phenobarbital in subcutaneous extracellular fluid and subdural cerebrospinal fluid in humans: an in vitro and in vivo study of adsorption to the sampling device. Pharmacol. Toxicol. 2002, 91:158-165.
167. Tholance Y., Barcelos G., Quadrio I., et al. Analytical validation of MD analyzer for monitoring glucose, lactate and pyruvate in cerebral MDs. Clin. Chim. Acta 2011, 412:647-654.
168. Hutchinson P.J., Gimson A., Al-Rawi P.G., et al. MD in the management of hepatic encephalopathy. Neurocrit. Care 2006, 5:202-205.
169. Hutchinson P.J., O'Connell M.T., AI-Rawi P.G., et al. Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids. J. Neurol. Neurosurg. Psychiatry 2002, 72:99-105.
170. Sarrafzadeh A.S., Kiening K.L., Callsen T.A., et al. Metabolic changes during impending and manifest cerebral hypoxia in traumatic brain injury. Br. J. Neurosurg. 2003, 17:340-346.
171. Mendelowitsch A. Microdialysis: intraoperative and posttraumatic applications in neurosurgery. Methods 2001, 23:73-81.
172. Blakeley J., Portnow J. MD for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin. Drug Metab. Toxicol. 2010, 6:1477-1491.
173. Ungerstedt U., Pycock C. Functional correlates of dopamine neurotransmission. Bull. Schweiz. Akad. Med. Wiss. 1974, 30:44-55.